T he much-heralded promise of the genomic era relies on rigorous research into common, complex diseases. In stroke as with many other neurological diseases, severely affected phenotypes are associated with impaired capacity to make informed well-reasoned decisions, 1 and phenotypic severity may be in part genetically determined. 2, 3 For these disorders, research into genetic risk warrants consideration for inclusion of individuals with impaired capacity.
Investigators and investigational review boards (IRBs) lack clear guidance from federal regulations regarding acceptability of including adults with impaired capacity to consent in genetic research. 4, 5 Little is known about IRB and investigator practices in research not offering prospect of direct benefit to participants, as noted by the U.S. Office of Human Research Protections in a recent call for comments on this topic. 6 We conducted sequential cross-sectional investigator surveys to determine how often IRBs allow enrollment by surrogate authorization of impaired adults as probands in "nontherapeutic" genetic research and to ascertain how often investigators enroll impaired individuals when they have IRB approval to do so.
Materials and Methods
We surveyed investigators from a multi-center North American affected sibling pair study known as the Siblings with Ischemic Stroke Study (SWISS). SWISS includes a genome-wide screen to identify novel risk factors through linkage analysis in sibling pairs concordant and discordant for ischemic stroke. 7 For probands meeting eligibility criteria, participation includes sending letters to siblings inviting participation and providing a blood sample for genetic analysis if at least one qualified sibling also agrees to participate; samples are double-coded. 8 Probands give their own written informed consent if able, and if unable, are enrolled through a variety of mechanisms as permitted by the local governing IRB. SWISS does not use a central IRB.
We surveyed all actively enrolling sites during the recruitment phase of the study in 2003 (nϭ49 centers) and again in 2007 (nϭ53 centers). Between surveys, 10 sites closed to enrollment, and 14 new centers started to enroll. The 2003 questions were part of a larger survey. 9 In 2007, investigators and coordinators at the 53 sites were surveyed on experiences related to adults felt to be impaired in their capacity to provide consent; responses were collected via email, fax, and in person at investigator meetings. Survey instruments were coded to ensure nonduplication of data. No identifiers were recorded. Data were collected in an anonymized fashion precluding pair-wise statistical analysis across the two survey epochs. The University of Virginia IRB approved the study. 
Results
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Discussion
In ischemic stroke, severe outcomes cause decisional impairment and severity may have genetic determinants. 2 In many other brain disorders like Alzheimer Disease, subarachnoid hemorrhage, and traumatic brain injury, phenotypic severity is also associated with impaired capacity and may have genetic determinants. 10 -12 Thus, scientifically valid research in these common brain disorders may require inclusion of decisionally-impaired individuals. 1, 13 This type of research would meet the "necessity" standard that decisionallyimpaired individuals be considered for research if and only if their participation is necessary to ensure scientific validity of socially, scientifically, or clinically valuable research. 14 -16 Genomic research in common brain disorders is a national priority. 17 Despite its potential to advance medicine and benefit future individuals, genomic research does not offer direct benefit to participants. This research underscores the challenge of simultaneously addressing the ethical requirements for "valuable research," "scientific validity," and "respecting persons." 15, 18 Respecting persons is generally met through the processes of informed consent for individuals having capacity or use of appropriate safeguards for individuals lacking capacity. Acceptable safeguards include excluding these individuals from research if their participation does not meet the necessity requirement or enrolling them via processes such as surrogate authorization, use of research advance directives, and awaiting return of capacity. 5, 14, 16, 18 In SWISS, sites enrolling individuals unable to provide their own consent used both surrogate authorization and return of capacity to some extent. Research advance directives were not used. In our study, approximately 40% of IRBs do not permit surrogate authorization. Fewer than half of sites encountering potential participants lacking decision-making capacity enrolled these individuals. In both surveys, sites allowed to use surrogate authorization were more likely to enroll impaired probands than sites not allowed use of surrogate authorization. However, most sites allowed to use surrogate authorization did not enroll any impaired individuals.
IRBs can deny surrogate enrollment based on concerns over the appropriateness of the practice or an assessment of excessive risk even for research meeting the "necessity" standard. We are not aware of any statute prohibiting enrollment of decisionally-impaired individuals or use of surrogate authorization in genetic research. When there is no prospect of direct benefit, surrogate enrollment in research with minimal risk is generally permitted, following the spirit of federal regulations pertaining to research with children, as the regulations are silent on this issue with respect to adults. 4, 6, 18 The regulations governing children also permit some research that involves a minor increment over minimal risk, even if the research does not offer prospect of direct benefit to the child-research participant, if the research is likely to yield generalizable knowledge about the subjects' disorder. 4 Granted, the federal regulations governing research involving children do not forestall continued debate over how best to determine the risks associated with research and the acceptability of various risks among children. 19 -21 Nevertheless, they can serve as a helpful framework when considering the enrollment in research of adults who lack the capacity to provide their own informed consent, a group currently not addressed by these regulations. 18 Risks associated with genomic research are not well documented, and beliefs regarding these risks vary greatly. 5, [22] [23] [24] [25] [26] It is unlikely that risks in genomic research are always higher than in other types of research where surrogate enrollment of adults is allowed, which can carry significant risk to participants with no guarantee of benefit, though the possibility of benefit exists. 27 Thus, a categorical prohibition against enrolling decisionally-impaired adults in genetic research on basis of risk seems unjustified. Nevertheless, some IRBs may judge the risk, even when minimal, to be too great to allow surrogate enrollment. In SWISS, the risk associated with participating is that of sending a letter inviting siblings to participate and of giving a double-coded blood sample for genome-wide scan and linkage analysis. More documentation of actual risks associated with genetic research overall, and with specific procedures used, would advance this debate.
In circumstances where surrogate enrollment is allowed, our results suggest that it is underutilized. We are unable to ascertain whether this results from researchers not approaching decisionally-impaired individuals, even when allowed; inability to locate a surrogate; surrogate refusal for study participation; or something else entirely. Researchers in many other brain disorders also find that use of surrogate decision-makers in research is not straightforward ethically or practically. 16, 28 The two other mechanisms, research advance directives and awaiting return of decision-making ability, are unfortunately not feasible alternatives. Research advance directives are difficult to implement when decline in decision-making capacity is anticipated such as in Alzheimer disease; in stroke and other unanticipated and apoplectic conditions like traumatic brain injury, implementation is even more difficult. 29 -31 No site in our study reported use of research advance directives. Some investigators waited for sufficient stroke recovery to obtain informed consent. However, because of high case-fatality or persistence of cognitive impairment in the most severe presentations of many brain disorders, awaiting return of capacity to make decisions may perpetuate enrollment bias. 1 Therefore, although reasonable from the point of view of respecting informed consent, it does little to relieve concerns over scientific validity.
In general, the term consent bias is applied to the negative effect on external validity attributable to individuals declining to participate in research. Consent bias in clinical trials research has been well recognized. 32, 33 More recently, attention has been paid to the impact of consent bias in observational, epidemiological, and etiologic research. 34 -37 Data also support a negative effect of consent bias on the representativeness of DNA banks. 38 These studies underscore the potential for skewing of data by requiring explicit consent and the need for strategies to address this type of bias. When the determinants of severity are some of the very factors sought in the studies or on the same causal pathways, there is potential for significant confounding and at worst may completely obscure important associations. Thus, the "consentability" bias introduced by restricting enrollment to those able to provide their own consent is more akin to survival bias, a potentially more problematic form of bias. 1 Our survey addresses the issue of enrolling individuals with impaired decision-making capability in the context of a single multisite study at 2 time points. The large number of sites and the high response rates are strengths. Furthermore, rather than use hypothetical scenarios, we surveyed actual practice. Focusing on investigators at sites participating in stroke genetics research may skew our results regarding IRB approvals. However, if there is a bias in our sample, it likely favors allowing surrogate enrollment, which suggests the actual percentage prohibiting surrogate enrollment may be higher than our estimate of 40%.
Our study does not seek explanations for current IRB and investigator practices. Nonetheless, at least in practice, many IRBs appear to treat genetic research as carrying considerable risks to participants by prohibiting surrogate authorization. 24 Clearly, further research to verify our findings and determine reasoning behind IRB and investigator decisions is needed, as is further inquiry regarding level of risk and other ethical issues in enrolling decisionally-impaired adults in genetics research.
Summary
Currently, there are few viable strategies for enrolling decisionally-impaired adults in genetic studies, even when their enrollment may be necessary for scientific validity. Enrollment by surrogate authorization is one such strategy that is frequently allowed in other types of research. We find that use of surrogate authorization is frequently not permitted or is underutilized in genomic research. This situation has implications for scientific validity of genomic research on many brain disorders of public health significance.
